ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Sclerosis (MS) in Milano, Lombardia

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Multiple Sclerosis
Chronic Progressive Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Sclerosis
Recurrence
Autoimmune Diseases
Myasthenia Gravis

Multiple Sclerosis (MS) trials near Milano, Lombardia, ITA:

A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) (PORTAMENTO)

SC reference formulation in participants with either relapsing multiple sclerosis (RMS) or primary progressive multiple sc...

Active, not recruiting
Multiple Sclerosis
Drug: Ocrelizumab Reference Formulation
Drug: Ocrelizumab Test Formulation

Phase 2

Roche
Roche

Milan, Lombardy, Italy and 50 other locations

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS...

Active, not recruiting
Multiple Sclerosis
Drug: Interferon beta-1a
Drug: Placebo capsule

Phase 3

Novartis
Novartis

Gallarate, VA, Italy and 72 other locations

Locations recently updated

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS) (Mintaka)

The main purpose of this study is to assess the efficacy of RO7268489 in adults with progressive multiple sclerosis (PMS) receiving...

Enrolling
Progressive Multiple Sclerosis
Drug: RO7268489
Drug: Ocrelizumab

Phase 2

Roche
Roche

Milan, Lombardy, Italy and 107 other locations

A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis

(Part 1), a single-ascending subcutaneous (SC) dose (Part 2), and multiple ascending SC doses (Part 3), and multiple-ascending SC d ...

Enrolling
Multiple Sclerosis
Drug: RO7121932 SC
Drug: RO7121932 IV

Phase 1

Roche
Roche

Milan, Lombardy, Italy and 31 other locations

A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS) (Operetta 2)

This double-blind, double-dummy study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with...

Active, not recruiting
Relapsing-remitting Multiple Sclerosis
Drug: Fingolimod
Other: Ocrelizumab Placebo

Phase 3

Roche
Roche

Milan, Lombardy, Italy and 71 other locations

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis (REMASTER)

The purpose of this study is to provide efficacy and safety data for remibrutinib in patients with secondary progressive multiple sclerosis...

Enrolling
Secondary Progressive Multiple Sclerosis (SPMS)
Drug: Remibrutinib (blinded)
Drug: Placebo

Phase 3

Novartis
Novartis

Pavia, PV, Italy and 255 other locations

Clinical Impact Through AI-assisted MS Care - A Prospective Multi-center Study (PROCLAIM)

as measured by icobrain mr, on the detection of disease activity in multiple sclerosis, including the identification of smouldering...

Invitation-only
Multiple Sclerosis
Radiologically Isolated Syndrome
Device: quantitative brain MRI (icobrain mr)
Other: Standard of Care (SOC)
icometrix

Milan, Italy and 5 other locations

Locations recently updated

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)

To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)...

Active, not recruiting
Relapsing Multiple Sclerosis
Drug: Teriflunomide
Drug: Remibrutinib

Phase 3

Novartis
Novartis

Novara, Italy and 201 other locations

Locations recently updated

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)

To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)...

Active, not recruiting
Relapsing Multiple Sclerosis
Drug: Remibrutinib
Drug: Teriflunomide

Phase 3

Novartis
Novartis

Pavia, PV, Italy and 223 other locations

Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis (Frexcite)

of frexalimab q4w in male and female participants with RMS and nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with MS...

Enrolling
Multiple Sclerosis
Drug: Frexalimab
Drug: MRI contrast-enhancing preparations

Phase 3

Sanofi
Sanofi

Milan, Milano, Italy and 37 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems